Login to Your Account

Algenpantucel alarm bell: Newlink sinks, rethinks pursuit of Hyperacute loot

By Randy Osborne
Staff Writer

Tuesday, May 10, 2016

As Wall Street tossed another would-be pancreatic cancer therapy on the phase III scrap heap, Newlink Genetics Corp. CEO Charles Link said the firm is "evaluating the future" of the Hyperacute Cellular Immunotherapy platform.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription